



## Insights Into Multiple Myeloma

### Saturday, August 15, 2020

Speaker: Melissa Alsina, MD

Moderator: Alexis M. Cruz-Chacon, MD

#### AGENDA

Time (ET/AST)	Topic
9.00 AM – 9.15 AM (15 min)	<b>Introduction</b> <ul style="list-style-type: none"> <li>• Program overview</li> <li>• Baseline ARS questions</li> </ul>
9.15 AM – 9.45 AM (30 min)	<b>Treatment of Newly Diagnosed Multiple Myeloma</b> <ul style="list-style-type: none"> <li>• Overview of current data <ul style="list-style-type: none"> <li>– Risk stratification</li> <li>– Selection of induction therapy for transplant-eligible and -ineligible patients</li> <li>– Incorporation of 4-drug regimens <ul style="list-style-type: none"> <li>▪ Dara-KRd</li> <li>▪ Integration of subcutaneous daratumumab</li> </ul> </li> <li>– Transplant: eligibility, timing</li> <li>– Maintenance therapy: which patients, which agents (lenalidomide, bortezomib, now ixazomib?), for how long?</li> <li>– Evolving role of MRD in multiple myeloma</li> <li>– Impact of COVID-19</li> </ul> </li> </ul>
9.45 AM – 10.15 AM (30 min)	<b>Moderated Discussion</b>
10.15 AM – 10.30 AM (15 min)	<b>Break</b>
10.30 AM – 10.50 AM (20 min)	<b>Treatment of Patients in Early Relapse</b> <ul style="list-style-type: none"> <li>• ARS questions</li> <li>• Overview of current data <ul style="list-style-type: none"> <li>– What is the optimal approach for patients progressing after 1 prior line of therapy? <ul style="list-style-type: none"> <li>▪ How are/will 3-drug combinations with mAbs vs proteasome inhibitors (or both) be incorporated into practice? <ul style="list-style-type: none"> <li>• CANDOR trial (KdD vs Kd)</li> </ul> </li> <li>▪ Existing data (RVd, KRd, IRd, ERd, EVd) and new results (eg, PVd)</li> <li>▪ Differentiation among PIs: bortezomib, carfilzomib, ixazomib</li> </ul> </li> <li>– Optimal integration of mAbs: elotuzumab, daratumumab <ul style="list-style-type: none"> <li>▪ Impact of prior therapy, depth and duration of prior response</li> </ul> </li> </ul> </li> </ul>
10.50 AM – 11.10 AM (20 min)	<b>Moderated Discussion</b>

<p>11.10 AM – 11.30 AM (20 min)</p>	<p><b>Treatment of Patients in Later Relapse</b></p> <ul style="list-style-type: none"> <li>• ARS questions</li> <li>• Overview of current data <ul style="list-style-type: none"> <li>– Approach to treatment of patients progressing after <math>\geq 2</math> prior regimens <ul style="list-style-type: none"> <li>▪ Impact of prior therapy on selection among pomalidomide, daratumumab, or other</li> <li>▪ Weekly vs twice-weekly carfilzomib plus dexamethasone</li> <li>▪ Incorporation of selinexor and venetoclax</li> </ul> </li> <li>– Impact of prior treatment, patient characteristics, and residual toxicities</li> <li>– Focus on emerging options: immune checkpoint inhibitors, CAR T therapy, bispecific antibodies?</li> </ul> </li> <li>• Reaction and discussion</li> </ul>
<p>11.30 AM – 11.50 AM (20 min)</p>	<p><b>Moderated Discussion</b></p>
<p>11.50 AM – 12.00 PM (10 min)</p>	<p><b>Key Takeaways and Meeting Evaluation</b></p>